Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
Fani Karagianni, Christina Piperi, Vassiliki Mpakou, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248298-e0248298
Open Access | Times Cited: 21

Showing 21 citing articles:

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma
Alisha Kashyap, Julia Dai, Xiao Ni
Cancers (2025) Vol. 17, Iss. 4, pp. 568-568
Open Access | Times Cited: 1
Retinoids as anti-cancer agents and their mechanisms of action.
Ying Hua Jin, Soek Sin Teh, Harrison Lik Nang Lau, et al.
PubMed (2022) Vol. 12, Iss. 3, pp. 938-960
Closed Access | Times Cited: 30
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Amit Kumar, Luni Emdad, Paul B. Fisher, et al.
Advances in cancer research (2023), pp. 73-161
Closed Access | Times Cited: 15
Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas
Karol Kołkowski, Magdalena Trzeciak, Małgorzata Sokołowska‐Wojdyło
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13388-13388
Open Access | Times Cited: 24
Advances in classification and treatment of primary cutaneous lymphomas
Hong Zheng, Lihua Qiu, Chang Liu, et al.
Annals of Hematology (2025)
Open Access
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
Klara R. Klein, Dagmar Stoiber, Veronika Sexl, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2611-2611
Open Access | Times Cited: 21
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Jingjing Ren, Rihao Qu, Nur-Taz Rahman, et al.
Blood Advances (2022) Vol. 7, Iss. 3, pp. 445-457
Open Access | Times Cited: 14
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
Fani Karagianni, Christina Piperi, Berta Casar, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1070-1070
Open Access | Times Cited: 13
Epigenetic alterations and advancement of lymphoma treatment
Shuhui Zhuang, Zhaobo Yang, Zhuangzhuang Cui, et al.
Annals of Hematology (2023) Vol. 103, Iss. 5, pp. 1435-1454
Closed Access | Times Cited: 8
Synthetic Approaches and Clinical Applications of Representative HDAC Inhibitors for Cancer Therapy: A Review
Zhiyi Lv, Tianyi Ji, Jie Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117185-117185
Closed Access | Times Cited: 2
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
Iman Quadri, John Reneau, Walter Hanel, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line
Esin Güvenir Çelik, Onur Eroğlu
Molecular Biology Reports (2022) Vol. 50, Iss. 1, pp. 319-329
Closed Access | Times Cited: 9
Therapeutic Opportunities in Cutaneous T-cell Lymphoma
Sara Valero‐Díaz, Camilla Amato, Berta Casar
(2024)
Open Access | Times Cited: 1
Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma
Sara Valero‐Díaz, Camilla Amato, Berta Casar
Kinases and Phosphatases (2024) Vol. 2, Iss. 3, pp. 255-267
Open Access | Times Cited: 1
The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities
Kalyani Patil, Gulab Sher, Shilpa Kuttikrishnan, et al.
Seminars in Cell and Developmental Biology (2022) Vol. 154, pp. 239-249
Open Access | Times Cited: 6
Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma
Shuichi Nakai, Eiji Kiyohara, Rei Watanabe
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12933-12933
Open Access | Times Cited: 7
Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas
Makoto Sugaya
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11079-11079
Open Access | Times Cited: 6
Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers
Boheng Li, Qin Wan, Zhubo Li, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5147-5147
Open Access | Times Cited: 5
Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma
Fani Karagianni, Christina Piperi, Sara Valero‐Díaz, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3176-3176
Open Access
Treatment of Sezary Syndrome with Combination Romidepsin and Tofacitinib: a Case Report
Sara Suhl, Brigit A. Lapolla, Alexander J. Kaminsky, et al.
JAAD Case Reports (2024) Vol. 55, pp. 69-72
Open Access
Ruxolitinib attenuates acute rejection and can serve as an immune induction therapy in heart transplantation
Yuan Chang, Mengda Xu, Yuxin Zhang, et al.
Clinical Immunology (2023) Vol. 257, pp. 109851-109851
Closed Access
Page 1

Scroll to top